About Cartiva

Central to the success of any medical device company is a team of experienced leaders with a proven track record of success. Cartiva has built an exceptionally talented management team of executives with significant experience in developing and commercializing innovative medical devices and building successful companies.

Timothy Patrick

President and CEO

Tim is the President, Chief Executive Officer and co-founder of Cartiva. Tim has over 30 years of successful leadership experience in general management and product commercialization in the medical device industry. Prior to founding Cartiva, Tim was President and CEO of Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005.

Prior to co-founding Proxima Therapeutics in 1996, Tim was President of Gesco International, the leading manufacturer of peripherally inserted central venous catheters, acquired by C.R. Bard. Before serving as President of Gesco International, he ran two high growth divisions for McGaw Inc., an infusion equipment and drug delivery company which was acquired by B. Braun. He also held a number of sales and sales management positions at American Hospital Supply Corporation.

Tim has served on the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the Board of the Georgia Tech Coulter Grant Committee and on the Board of Georgia Bio. Tim is an inventor on a number of medical device patents. He earned his BA in Zoology from Miami University in Ohio.

Aaron Berutti

Vice President, Business Development

Aaron has been Vice President, Business Development of Cartiva since February 2018. From 2004 until he joined Cartiva, Aaron served in various sales positions at Wright Medical Technology, Inc., a global medical device company focused on extremities and biologics products, including Corporate Sales Manager, Senior Corporate Sales Manager, Senior Director, U.S. Sales & Marketing Operations and, most recently, as Vice President, U.S. Sales. Prior to joining Wright Aaron was an independent orthopedic sales representative.

Aaron earned a Bachelor of Engineering degree from Vanderbilt University and a Master of Science in Finance and a Master of Business Administration from Indiana University.

Richard Knostman

Vice President, Operations

Rick has been Vice President, Operations of Cartiva since its founding. From 2001 until joining Cartiva, Rick was the Vice President, Operations for Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005.

Prior to joining Proxima, Rick served as Division Vice President of Operations for Bard Access Systems, the world’s leading manufacturer of vascular access catheters and ports and a division of C.R. Bard, Inc. Prior to his position with Bard, he was Vice President of Operations for Gesco International, a division of MedChem Products that was acquired by Bard in 1996. Rick also worked at Baxter Healthcare Corporation for 17 years, serving in positions that included plant manager, division planning manager and production manager.

An inventor on several patents, Rick earned a Bachelor of Science degree in Microbiology from the University of Arizona, Tucson.

Deborah Moore

Vice President, Regulatory, Quality & Clinical Affairs

Debbie has been Vice President, Regulatory, Quality & Clinical Affairs of Cartiva since its founding. Debbie has 25 years of experience in developing regulatory and clinical strategy, designing clinical trials and obtaining regulatory approvals and clearances for novel therapeutic technologies. From 1998 until joining Cartiva, Debbie was Vice President, Regulatory, Quality, and Clinical Affairs for Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005.

Prior to joining Proxima, she served as the Director of Regulatory and Clinical Affairs for Dornier Medical Systems, a leader in urologic medical devices. She successfully managed Dornier’s regulatory submissions, multi-center clinical trials and quality system.

Prior to joining Dornier, she was responsible for regulatory and quality affairs at Technomed International, a leader in microwave technology for benign prostatic hyperplasia that was later acquired by EDAP TMS SA. Debbie earned a Bachelor of Science degree in Physics from Simmons College and a Bachelor of Science degree in Biomedical Engineering from Boston University.

Peter Pizzo

Vice President, Finance and Chief Financial Officer

Peter has been Vice President, Finance and Chief Financial Officer of Cartiva since its founding. From 2002 until joining Cartiva, Peter was the Vice President, Finance and Chief Financial Officer of Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005.

Prior to joining Proxima, he served in senior financial positions with Serologicals Corporation, a $150 million publicly traded provider of biological products to life science companies, the last two years as Vice President of Finance and Chief Financial Officer. He previously served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals, and in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company.

Peter currently serves on the board of Alimera Sciences, Inc. (Nasdaq: ALIM) an ophthalmic pharmaceutical company, where he chairs the audit committee and is a member of the nominating and corporate governance committee. Peter earned a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University.

Carribeth Ramey

Vice President, Engineering and Cartiva Manufacturing

Carribeth has been Vice President, Engineering of Cartiva since June 2014. She joined Cartiva as Director, Engineering and was promoted to vice president in May 2014. From 2001 until joining Cartiva, Carribeth was Senior Product Development Engineer at Proxima Therapeutics, Inc., a medical device company that developed and marketed innovative local radiation delivery systems for the treatment of solid cancerous tumors. Proxima was acquired by Cytyc Corporation in March 2005.

Prior to joining Proxima, Carribeth held research engineering positions at CryoLife Incorporated, focusing on biomaterial and xenograft heart valve development in the areas of hydrodynamics and biomechanics. Carribeth is an inventor on several patents related to automated injection systems and others related to localized radiation delivery systems. Carribeth earned a Bachelor of Science degree in Mechanical Engineering from The Georgia Institute of Technology and was inducted into the Georgia Institute of Technology’s Council of Outstanding Young Engineering Alumni.

Bobby Singer

Vice President, Sales

Bobby has been Vice President, Sales of Cartiva since its acquisition of SaluMedica, LLC in 2008. SaluMedica developed the Cartiva Synthetic Cartilage Implant using its proprietary biomaterial technology. Bobby joined SaluMedica as Vice President of Sales in 2004 focusing on international growth. In 2007, he was promoted to President and became a member of the company’s Board of Directors.

Prior to joining SaluMedica, Bobby served as Vice President of Sales for Horizon Medical Products Inc., a manufacturer and distributor of general and vascular surgery products used in the treatment of oncology patients. Before leading worldwide sales, he held positions as National Sales Manager, Regional Sales Manager and early in his 15 years with Horizon, covered the Georgia territory as a sales representative.

Bobby earned his Bachelor of Arts in Communication from Mercer University.

Katie Strother

Vice President, Medical Education

Katie has been Vice President, Medical Education since November 2016. Prior to her current role, she served as Cartiva’s Director, Clinical Affairs since joining Cartiva in 2008.  Katie has over 15 years of experience in global clinical trial development, execution and management.  She has significant therapeutic trial experience including orthopaedic devices, oncology, transplant, neurology and endocrinology.

Prior to joining Cartiva, Katie served as a Project Manager for Clinimetrics Research Associates, a full service Contract Research Organization (CRO) focused on study management for biotechnology and early stage pharmaceutical and medical device companies.  At Clinimetrics, she successfully managed Phase II and Phase III global multi-center clinical trials for one of the Top 20 pharmaceutical and biotech companies in the world.  Prior to joining Clinimetrics, Katie held clinical research positions with Quintiles, Emory University, Atlanta Veteran’s Administration Medical Center and the Kerr L. White Institute for Health Services Research.

Katie earned a Bachelor of Arts degree in Business/Economics and International Relations from Agnes Scott College.

Cartiva’s board of directors consists of leading investors, industry experts and researchers who have successful track records with numerous medical device, pharmaceutical and biotechnology companies.

Barbara Boyan, Ph.D.

Dean, School of Engineering

Virginia Commonwealth University

Barbara, a Cartiva director since 2011, is Professor and the Alice T. and William H. Goodwin Chair in Biomedical Engineering and Dean, School of Engineering at the Virginia Commonwealth University in Richmond, VA.  In addition, she is an emeritus professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University where she held the Price Gilbert, Jr. Chair in Tissue Engineering from 2002 until 2012.

Barbara was a Georgia Research Alliance Eminent Scholar and Associate Dean for Research and Innovation in the College of Engineering of the Georgia Institute of Technology.  She was also director of the Children’s Healthcare of Atlanta’s Center for Pediatric Healthcare Technology Innovation, the Atlanta Pediatric Device Consortium and Georgia Tech’s Translational Research Institute for Biomedical Engineering and Science.  Barbara is a past chair of the Orthopaedic Device Panel of the FDA and a past president of the American Association of Dental Research.  She is a Fellow in the American Association for the Advancement of Science and the American Institute of Mechanical and Biomedical. 

Barbara holds a B.A., M.A. and Ph.D. in biology from Rice University. 

Ryan Drant

Founder & Managing Director

Questa Capital Management

Ryan, a director since 2011, is the Founder and Managing Director of Questa Capital, a healthcare-focused private investment firm. From 1996 to 2016 Ryan was a partner at New Enterprise Associates, where he served as a general partner, head of the healthcare investing team and a member of NEA’s management committee. Prior to NEA, he was in the corporate finance group at Alex. Brown & Sons and started his career at Arthur Andersen & Co. Ryan is a four-time nominee to the Forbes Midas List of top venture capital investors. In addition to Cartiva, he is currently a director of Carticept Medical, Intrinsic Therapeutics,  Radiology Partners, Solace Therapeutics, SyncHR, EPiX Therapeutics, Medrio, Dispatch Health and Spine Wave. Ryan also serves on the board of the Medical Device Manufacturers Association. He received a Bachelor of Arts degree in Political Science from Stanford University.

Justin Klein, MD, JD


New Enterprise Associates (NEA)

Justin, a director since 2013, joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology and biopharmaceutical company investments.  He serves as a director of Advanced Cardiac Therapeutics,  FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics (NYSE: SENS), VertiFlex, and VytronUS. He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee.

Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations—as Duke built one of the nation's first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.

Bob More

Managing Director

Alta Partners

Bob, a director since 2011, joined Alta Partners, a leading life sciences venture capital firm, in October 2015. From July 2013 until July 2015, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.” From 2008 until he joined the Gates Foundation, he was a General Partner and a member of the Biopharma Venture team at Frazier Healthcare. Prior to Frazier Healthcare, Bob was a Partner with Domain Associates, having joined the firm in 1996 as a Kauffman Fellow and becoming a Partner in 2000.

From 1997 to1998, Bob served as the Chief Operating Officer of Small Molecule Therapeutics, a Domain portfolio company subsequently purchased by Morphochem AG., and from 1992 to 1995, was in sales at Pharmacia Biotech. Prior to joining Pharmacia, Bob held a research position at Somatogen, a company developing a recombinant blood substitute that was subsequently bought by Baxter. While attending business school, Mr. More worked with MedVest, an early-stage venture group in Washington, D.C. Bob serves as an advisory board member for Greenspring Associates, Okapi Ventures, The Medical Industry Group of the NVCA and The Sulpizio Family Cardiovascular Center.

He is also a past founding board member of the Kauffman Fellows Program. Bob received his M.B.A. from the Darden School of Business Administration at the University of Virginia and a B.A. from Middlebury College.

Timothy Patrick

President and Chief Executive Officer

Cartiva, Inc.

Eric Stookey

Chief Operating Officer

OsteoRemedies, LLC

Eric, a director since January 2015, has been Chief Operating Officer of OsteoRemedies, LLC, a company with the first FDA-cleared modular system for two-stage revision of infected hip and knee total joints, since March of 2015. Prior to joining OsteoRemedies, Eric served as the President of the Extremities & Biologics division at Wright Medical Group, Inc. (Nasdaq:WMGI) until August 2014. Eric served in various other marketing and sales positions at Wright Medical Group, Inc. since 1995, including as the Senior Vice President and Chief Commercial Officer from January 2010 to November 2011, as the Vice President North American Sales from 2007 to January 2010, as the Vice President US Sales from 2005 until 2007, as the Senior Director of Sales, Central Region, from 2003 to 2005 and as the Director of Marketing for Large Joint Reconstruction Products from 2001 to 2003. He was also employed by DePuy Orthopedics, Inc. from 1993 to 1995.

Eric, who earned his Masters of Business Administration degree from Christian Brothers University and his Bachelor of Science degree in Business from the Indiana University School of Business, currently serves on the board of Amedica Corporation (Nasdaq:AMDA), a biomaterial company focused on silicon nitride ceramics.

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $17 billion in cumulative committed capital since inception, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 200 portfolio company IPOs and more than 320 acquisitions.

Founded in 2006, Windham Venture Partners is a New York City based venture capital firm focused on healthcare technology, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of healthcare and information technology). Windham seeks to invest in and partner with companies that are commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors.

March 22, 2018

Synthetic cartilage an answer to osteoarthritis

CBS4 Indianapolis, IN

March 22, 2018

Synthetic cartilage an answer to osteoarthritis

CBS4 Indianapolis

July 26, 2017

Synthetic Cartilage Offers Relief From Osteoarthritis

CBS News syndicated nationally

June 19, 2017

New implant offers long-term treatment for arthritis

KMSP Fox 9 Minneapolis

March 13, 2017

Life-Changing New Treatment for Arthritis

NBC Nightly News with Lester Holt

February 20, 2017

New procedure helps treat big toe arthritis

WBAL Baltimore

November 02, 2016

Small implant relieves big toe pain

Duke Health

July 29, 2016

Implant provides hope for the limping


Cartiva, Inc. is a private medical device company based in the northern Atlanta suburb of Alpharetta, Georgia. Our team consists of highly-skilled professionals who are dedicated to improving the quality of life of patients with osteoarthritis, cartilage damage and other musculoskeletal conditions.

Our work environment is highly collaborative and our employees drive Cartiva’s friendly, fast-paced and energetic environment. We offer an engaging, small, entrepreneurial environment, which allows individuals to contribute, learn, grow and develop. We are always looking for motivated individuals who are interested in growth opportunities to join our vibrant team.